세계의 호흡기 질환 백신 시장 보고서(2025년)

Respiratory Disease Vaccine Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

호흡기 질환 백신 시장 규모는 향후 몇 년 동안 안정적인 성장을 보일 것으로 예상되며, 2029년까지 2.8%의 연평균 복합 성장률(CAGR)로 791억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 인구 고령화, 의료비 지출 증가, 백신 투자, 팬데믹 대응에 기인합니다. 예측 기간의 주요 동향으로는 혁신적인 백신, 공동 연구, 백신 개발의 진전, 의약품 승인 등이 있습니다.

결핵 발병률 증가가 호흡기 질환 백신 시장의 성장을 견인할 것으로 예상됩니다. 결핵은 주로 폐를 침범하는 심각한 감염성 질환으로 결핵균에 의해 발생합니다. 적절한 치료가 이루어지지 않으면 심각한 합병증을 유발할 수 있으며, 그 확산을 억제하기 위해서는 백신의 개발과 보급이 매우 중요합니다. 결핵 환자 증가는 전염을 줄이고 공중보건 성과를 개선하기 위해 백신 접종을 강화해야 할 필요성을 강조하고 있습니다. 예를 들어, 2023년 11월 미국 질병예방통제센터(CDC)는 2022년 미국에서 8,331명의 결핵 환자가 발생하여 2021년 대비 5.9% 증가했다고 보고했습니다. 유병률도 5.5% 상승하여 인구 10만 명당 2.5명에 달했습니다. 이러한 결핵 환자 증가 추세는 백신 및 기타 예방책에 대한 수요 증가를 의미하며, 호흡기 질환 백신 시장 확대에 박차를 가할 것으로 보입니다.

흡연율 증가는 호흡기 질환 백신 시장의 미래 성장 동력이 될 것으로 예상됩니다. 흡연은 담배나 담배를 포함한 제품의 연소 과정에서 발생하는 연기를 들이마시거나 내뿜는 행위로 기관지염, 심장병, 뇌졸중, 다양한 형태의 암 등 많은 건강상의 위험을 초래합니다. 호흡기 질환 백신은 흡연자에게 특정 감염으로부터 자신을 보호하는 중요한 역할을 합니다. 예를 들어, 2022년 7월 캐나다 통계청의 데이터에 따르면 2021년 6월에 비해 담배 생산량이 5.8% 증가했다고 합니다. 또한 담배 총 판매량은 2022년 5월 대비 1.3% 증가하여 2022년 6월에는 14억 개비에 달했습니다. 결과적으로 흡연율 증가는 호흡기 질환 백신 시장 확대의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 호흡기 질환 백신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업 분석
• 세계의 호흡기 질환 백신 시장 : 성장률 분석
• 세계의 호흡기 질환 백신 시장 실적 : 규모와 성장, 2019-2024
• 세계의 호흡기 질환 백신 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 호흡기 질환 백신 전체 시장(TAM)

제6장 시장 세분화

• 세계의 호흡기 질환 백신 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 바이러스 백신
• 세균 백신
• 혼합 백신
• 세계의 호흡기 질환 백신 시장 : 감염별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• COVID-19
• 인플루엔자
• 호흡기세포융합바이러스(RSV)
• 폐렴
• 기타 감염증
• 세계의 호흡기 질환 백신 시장 : 연령별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 유아
• 사춘기
• 성인
• 세계의 호흡기 질환 백신 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 클리닉
• 병원
• 기타 최종사용자
• 세계의 호흡기 질환 백신 시장 : 바이러스 백신 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 인플루엔자 백신
• RS 바이러스(RSV) 백신
• 코로나바이러스 백신
• 세계의 호흡기 질환 백신 시장 세균 백신 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 폐렴구균 백신
• 인플루엔자균 b형(Hib) 백신
• 백일해 백신
• 세계의 호흡기 질환 백신 시장 : 혼합 백신별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Hib와 IPV를 조합한 DTaP
• 폐렴구균 결합 백신 및 인플루엔자 백신
• MMRV

제7장 지역별/국가별 분석

• 세계의 호흡기 질환 백신 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 호흡기 질환 백신 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 호흡기 질환 백신 시장 : 경쟁 구도
• 호흡기 질환 백신 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• GlaxoSmithKline PLC
• Sinovac Biotech Co. Ltd.
• Moderna Inc.
• BioNTech SE
• CSL Limited
• Daiichi Sankyo Company Limited
• Mitsubishi Tanabe Pharma Corporation
• Novavax Inc.
• Emergent BioSolutions Inc.
• Seqirus
• Bio Farma
• Dynavax Technologies Corporation
• Hualan Biological Bacterin Co. Ltd.
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic A/S

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 호흡기 질환 백신 시장(2029년) : 새로운 기회를 제공하는 국가
• 호흡기 질환 백신 시장(2029년) : 새로운 기회를 제공하는 부문
• 호흡기 질환 백신 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Respiratory diseases encompass a broad spectrum of conditions that impact the airways and lungs, resulting in respiratory symptoms and compromised breathing. Respiratory disease vaccines, on the other hand, pertain to a category of immunizations specifically formulated to shield individuals from respiratory infections caused by viruses or bacteria that primarily target the respiratory system, which includes the lungs and air passages. These vaccines function by activating the immune system to generate antibodies capable of identifying and combatting the particular pathogens responsible for these diseases.

The primary classifications of respiratory disease vaccines encompass viral vaccines, bacterial vaccines, and combination vaccines. Viral vaccines consist of formulations containing weakened or inactivated viruses. They serve to stimulate immune responses and are instrumental in the prevention of respiratory diseases by instructing the immune system to recognize and mount defenses against distinct viruses. This, in turn, reduces the spread and severity of infections. These vaccines find application in combatting illnesses such as COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, among others, and are administered to individuals spanning various age groups, including infants, adolescents, and adults, within clinical, hospital, and other healthcare settings.

The respiratory diseases vaccine market research report is one of a series of new reports from The Business Research Company that provides respiratory diseases vaccine market statistics, including respiratory diseases vaccine industry global market size, regional shares, competitors with a respiratory diseases vaccine market share, detailed respiratory diseases vaccine market segments, market trends and opportunities and any further data you may need to thrive in the respiratory diseases vaccine industry. This respiratory diseases vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory disease vaccine market size has grown marginally in recent years. It will grow from $69.99 billion in 2024 to $70.9 billion in 2025 at a compound annual growth rate (CAGR) of 1.3%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, growing demand for effective and more tolerable vaccines.

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $79.16 billion in 2029 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, investments in vaccine, pandemic preparedness. Major trends in the forecast period include innovative vaccines, collaborative research, advancement in vaccine development, drug approval.

The increasing incidence of tuberculosis (TB) is expected to drive the growth of the respiratory disease vaccine market. TB is a serious infectious disease primarily affecting the lungs, caused by the bacterium Mycobacterium tuberculosis. It can lead to severe complications if not treated adequately, making the development and distribution of vaccines crucial in controlling its spread. The rising number of TB cases has highlighted the need for enhanced vaccination efforts to reduce transmission and improve public health outcomes. For example, in November 2023, the Centers for Disease Control and Prevention (CDC) reported that the United States saw 8,331 TB cases in 2022, marking a 5.9% increase compared to 2021. The incidence rate also rose by 5.5%, reaching 2.5 cases per 100,000 people. This upward trend in TB cases underlines the growing demand for vaccines and other preventive measures, which in turn will fuel the expansion of the respiratory disease vaccine market.

The increasing prevalence of smoking is poised to be a driving factor in the prospective growth of the respiratory disease vaccine market. Smoking entails the inhalation and exhalation of smoke emanating from the combustion of tobacco or tobacco-containing products, posing a multitude of health hazards, including tracheitis, heart disease, stroke, and various forms of cancer. Respiratory disease vaccines play a crucial role in providing a measure of protection against specific infections for individuals who engage in smoking. For instance, data from Statistics Canada in July 2022 highlighted a 5.8% upsurge in cigarette production compared to June 2021. Additionally, the total volume of cigarettes sold increased by 1.3% from May 2022, reaching a total of 1.4 billion in June 2022. Consequently, the growing incidence of smoking is a driving force behind the expansion of the respiratory disease vaccine market.

Leading companies in the respiratory disease vaccine market are committed to the development of innovative products aimed at bolstering their effectiveness, providing advanced solutions for the prevention and treatment of respiratory infections. For instance, in May 2023, Pfizer Inc., a U.S.-based pharmaceutical company, secured approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent vaccine, featuring the respiratory syncytial virus prefusion F (RSVpreF) vaccine, is designed for the prevention of lower respiratory tract disease stemming from respiratory syncytial virus in individuals aged 60 years and above. ABRYSVO comprises unadjuvanted vaccine components, with two preF proteins meticulously tailored to optimize immunity against both RSV A and B strains. Clinical trials have demonstrated the vaccine's safety and efficacy.

In August 2022, GSK PLC, a biopharmaceutical company headquartered in the UK, completed the acquisition of Affinivax Inc. The financial details of the acquisition were not disclosed. This strategic move reaffirms GSK Plc's dedication to innovation in the realm of pharmaceuticals and vaccines, including its commitment to the development of a next-generation 24-valent pneumococcal vaccine candidate known as AFX3772. Affinivax Inc., a clinical-stage biotechnology company based in the United States, specializes in the development of vaccines and immunotherapies targeted at a range of diseases, with a particular focus on respiratory ailments.

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the respiratory diseases vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory diseases vaccine market consists of sales of the rotavirus vaccine, bordetella vaccine and varicella (chickenpox) vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Disease Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory disease vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
• 2) By Infection: COVID-19; Influenza; Respiratory Syncytial Virus (RSV); Pneumonia; Other Infections
• 3) By Age: Infant; Adolescent; Adult
• 4) By End-User: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Viral Vaccine: Influenza Vaccine; Respiratory Syncytial Virus (RSV) Vaccine; Coronavirus Vaccine
• 2) By Bacterial Vaccine: Pneumococcal Vaccine; Haemophilus Influenzae Type B (Hib) Vaccine; Pertussis Vaccine
• 3) By Combination Vaccine: DTaP With Hib And IPV; Pneumococcal Conjugate Vaccine With Influenza Vaccine; MMRV
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; Merck & Co. Inc.; Sanofi SA; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Respiratory Disease Vaccine Market Characteristics

3. Respiratory Disease Vaccine Market Trends And Strategies

4. Respiratory Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Respiratory Disease Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Respiratory Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Respiratory Disease Vaccine Market Growth Rate Analysis
• 5.4. Global Respiratory Disease Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Respiratory Disease Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Respiratory Disease Vaccine Total Addressable Market (TAM)

6. Respiratory Disease Vaccine Market Segmentation

• 6.1. Global Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Vaccine
• Bacterial Vaccine
• Combination Vaccine
• 6.2. Global Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• COVID-19
• Influenza
• Respiratory Syncytial Virus (RSV)
• Pneumonia
• Other Infections
• 6.3. Global Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infant
• Adolescent
• Adult
• 6.4. Global Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End-Users
• 6.5. Global Respiratory Disease Vaccine Market, Sub-Segmentation Of Viral Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza Vaccine
• Respiratory Syncytial Virus (RSV) Vaccine
• Coronavirus Vaccine
• 6.6. Global Respiratory Disease Vaccine Market, Sub-Segmentation Of Bacterial Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumococcal Vaccine
• Haemophilus Influenzae Type B (Hib) Vaccine
• Pertussis Vaccine
• 6.7. Global Respiratory Disease Vaccine Market, Sub-Segmentation Of Combination Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DTaP With Hib And IPV
• Pneumococcal Conjugate Vaccine With Influenza Vaccine
• MMRV

7. Respiratory Disease Vaccine Market Regional And Country Analysis

• 7.1. Global Respiratory Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Respiratory Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Respiratory Disease Vaccine Market

• 8.1. Asia-Pacific Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Respiratory Disease Vaccine Market

• 9.1. China Respiratory Disease Vaccine Market Overview
• 9.2. China Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Respiratory Disease Vaccine Market

• 10.1. India Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Respiratory Disease Vaccine Market

• 11.1. Japan Respiratory Disease Vaccine Market Overview
• 11.2. Japan Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Respiratory Disease Vaccine Market

• 12.1. Australia Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Respiratory Disease Vaccine Market

• 13.1. Indonesia Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Respiratory Disease Vaccine Market

• 14.1. South Korea Respiratory Disease Vaccine Market Overview
• 14.2. South Korea Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Respiratory Disease Vaccine Market

• 15.1. Western Europe Respiratory Disease Vaccine Market Overview
• 15.2. Western Europe Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Respiratory Disease Vaccine Market

• 16.1. UK Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Respiratory Disease Vaccine Market

• 17.1. Germany Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Respiratory Disease Vaccine Market

• 18.1. France Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Respiratory Disease Vaccine Market

• 19.1. Italy Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Respiratory Disease Vaccine Market

• 20.1. Spain Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Respiratory Disease Vaccine Market

• 21.1. Eastern Europe Respiratory Disease Vaccine Market Overview
• 21.2. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Respiratory Disease Vaccine Market

• 22.1. Russia Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Respiratory Disease Vaccine Market

• 23.1. North America Respiratory Disease Vaccine Market Overview
• 23.2. North America Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Respiratory Disease Vaccine Market

• 24.1. USA Respiratory Disease Vaccine Market Overview
• 24.2. USA Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Respiratory Disease Vaccine Market

• 25.1. Canada Respiratory Disease Vaccine Market Overview
• 25.2. Canada Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Respiratory Disease Vaccine Market

• 26.1. South America Respiratory Disease Vaccine Market Overview
• 26.2. South America Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Respiratory Disease Vaccine Market

• 27.1. Brazil Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Respiratory Disease Vaccine Market

• 28.1. Middle East Respiratory Disease Vaccine Market Overview
• 28.2. Middle East Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Respiratory Disease Vaccine Market

• 29.1. Africa Respiratory Disease Vaccine Market Overview
• 29.2. Africa Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Respiratory Disease Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Respiratory Disease Vaccine Market Competitive Landscape
• 30.2. Respiratory Disease Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Respiratory Disease Vaccine Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline PLC
• 31.2. Sinovac Biotech Co. Ltd.
• 31.3. Moderna Inc.
• 31.4. BioNTech SE
• 31.5. CSL Limited
• 31.6. Daiichi Sankyo Company Limited
• 31.7. Mitsubishi Tanabe Pharma Corporation
• 31.8. Novavax Inc.
• 31.9. Emergent BioSolutions Inc.
• 31.10. Seqirus
• 31.11. Bio Farma
• 31.12. Dynavax Technologies Corporation
• 31.13. Hualan Biological Bacterin Co. Ltd.
• 31.14. Serum Institute of India Pvt. Ltd.
• 31.15. Bavarian Nordic A/S

32. Global Respiratory Disease Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Respiratory Disease Vaccine Market

34. Recent Developments In The Respiratory Disease Vaccine Market

35. Respiratory Disease Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Respiratory Disease Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Respiratory Disease Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Respiratory Disease Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료